Showing papers by "Rami I. Aqeilan published in 2002"
TL;DR: It is shown that upon entering their target cell, a variety of chimeric proteins composed of an endogenous protein as their killing moiety reach the subcellular location of their endogenous counterpart, in contrast to bacterial-based killing domains, which head for the sub cellular site of their substrate.
5 citations
30 May 2002
2 citations
TL;DR: This review presents new approaches for battling cancer, such as recruiting the apoptotic machinery via chimeric proteins, the use of receptor-mediated delivery of toxin-DNA, or T-cells as vehicles for delivering immunotoxins, all of which are trying to develop specific, efficient, nontoxic and non-immunogenic reagents for targeted cancer treatment.
Abstract: The rising rate of cancer-related diseases and mortality underscores the need for new approaches to directly target and light cancer. This review summarizes one of these new promising treatments, the use of targeted chimeric proteins. Chimeric proteins are two proteins fused at the DNA level in such a way that, once expressed, they result in a single polypeptide chain consisting of two moieties: a targeting moiety (usually a cytokine or growth lactor) and a killing moiety (usually a hacterial or plant texio). Many chimeric proteins have been constructed and developed over the years for the treatment of a variety of malignancies and these molecutes are the main scope of this review. Moreover, this review presents new approaches for battling cancer, such as recruiting the apoptotic machinery via chimeric proteins, the use of receptor-mediated delivery of toxin-DNA, or T-cells as vehicles for delivering immunotoxins, all of which are trying to develop specific, efficient, nontoxic and non-immunogenic reagents for targeted cancer treatment.
1 citations